90 related articles for article (PubMed ID: 38610938)
1. Sex-Specific Expression of Histone Lysine Demethylases (KDMs) in Thyroid Cancer.
Shobab L; Zheng H; Jensen K; Mendonca-Torres MC; McCoy M; Hoperia V; Rosen J; Wartofsky L; Burman K; Vasko V
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610938
[TBL] [Abstract][Full Text] [Related]
2. [Expression pattern of the histone lysine demethylase family and its potential role in bladder cancer: a multi-omics analysis].
Fu X; Yu G; Guo Y
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Dec; 42(12):1822-1831. PubMed ID: 36651250
[TBL] [Abstract][Full Text] [Related]
3. Histone 3 lysine 4, 9, and 27 demethylases expression profile in fertilized and cloned bovine and porcine embryos.
Glanzner WG; Rissi VB; de Macedo MP; Mujica LKS; Gutierrez K; Bridi A; de Souza JRM; Gonçalves PBD; Bordignon V
Biol Reprod; 2018 Jun; 98(6):742-751. PubMed ID: 29528362
[TBL] [Abstract][Full Text] [Related]
4. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
5. The role and prospect of lysine-specific demethylases in cancer chemoresistance.
Song YQ; Yang GJ; Ma DL; Wang W; Leung CH
Med Res Rev; 2023 Sep; 43(5):1438-1469. PubMed ID: 37012609
[TBL] [Abstract][Full Text] [Related]
6. Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
He X; Zhang H; Zhang Y; Ye Y; Wang S; Bai R; Xie T; Ye XY
Eur J Med Chem; 2022 Mar; 231():114143. PubMed ID: 35101649
[TBL] [Abstract][Full Text] [Related]
7. Correlations of m
Li X; Ding Z; Tong Y
Int J Gen Med; 2024; 17():775-790. PubMed ID: 38476625
[TBL] [Abstract][Full Text] [Related]
8.
Li S; Xue J; Jiang K; Chen Y; Zhu L; Liu R
Front Oncol; 2024; 14():1325345. PubMed ID: 38313800
[TBL] [Abstract][Full Text] [Related]
9. Nuclear transport proteins: structure, function, and disease relevance.
Yang Y; Guo L; Chen L; Gong B; Jia D; Sun Q
Signal Transduct Target Ther; 2023 Nov; 8(1):425. PubMed ID: 37945593
[TBL] [Abstract][Full Text] [Related]
10. XPO1-Mediated mRNA Export of Genome Maintenance Regulators Drives Chemotherapy Resistance in Aggressive Lymphoma.
Knittel G; Reinhardt HC
Cancer Res; 2024 Jan; 84(1):3-5. PubMed ID: 37902414
[TBL] [Abstract][Full Text] [Related]
11. Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma.
Liu H; Liu M; Tian X; Wang H; Gao J; Li H; Zhao Z; Liu Y; Liu C; Chen X; Yang Y
Elife; 2023 Oct; 12():. PubMed ID: 37888961
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in catalysis and inhibition of the Jumonji histone demethylases.
Sarah L; Fujimori DG
Curr Opin Struct Biol; 2023 Dec; 83():102707. PubMed ID: 37832177
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic control of pancreatic cancer metastasis.
Krauß L; Schneider C; Hessmann E; Saur D; Schneider G
Cancer Metastasis Rev; 2023 Dec; 42(4):1113-1131. PubMed ID: 37659057
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
